Athenex to Provide Corporate and Financial Update for the First Quarter 2021 on May 6, 2021
Athenex, Inc. (NASDAQ: ATNX) will present its first quarter 2021 corporate and financial update on May 6, 2021, prior to market opening. The management team will conduct a conference call at 8:00 am ET, with participation details including the domestic and international dial-in numbers provided. Athenex, dedicated to developing innovative cancer treatments, operates on three platforms and has an extensive clinical pipeline based on several technologies. For further details, visit Athenex's website.
- Scheduled corporate and financial update for Q1 2021 may provide insights into operational progress.
- Existing clinical pipeline focused on innovative therapies enhances market potential.
- Company's reliance on third-party performance presents operational risks.
- History of operating losses indicates ongoing financial challenges.
BUFFALO, N.Y., April 27, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the Company will provide a corporate and financial update for the first quarter 2021, on Thursday, May 6, 2021, before the market opens. Athenex’s management team will host a conference call and live audio webcast at 8:00 am Eastern Time.
To participate in the call, dial either the domestic or international number fifteen minutes before the conference call begins:
Domestic: (888) 771-4371
International: (847) 585-4405
Passcode: 50156178
The live conference call and replay can also be accessed via audio webcast at the Investor Relations section of the Company’s website, located at http://ir.athenex.com/.
About Athenex, Inc.
Founded in 2003, Athenex, Inc. is a global clinical stage biopharmaceutical company dedicated to becoming a leader in the discovery, development, and commercialization of next generation drugs for the treatment of cancer. Athenex is organized around three platforms, including an Oncology Innovation Platform, a Commercial Platform, and a Global Supply Chain Platform. The Company’s current clinical pipeline is derived from four different platform technologies: (1) Orascovery, based on P-glycoprotein inhibitor, (2) Src kinase inhibition, (3) T-cell receptor-engineered T-cells (TCR-T), and (4) Arginine deprivation therapy. Athenex’s employees worldwide are dedicated to improving the lives of cancer patients by creating more active and tolerable treatments. For more information, please visit www.athenex.com.
Forward-Looking Statements
Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements. These forward-looking statements are typically identified by terms such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “foresee,” “goal,” “guidance,” “intend,” “likely,” “may,” “plan,” “potential,” “predict,” “preliminary,” “probable,” “project,” “promising,” “seek,” “should,” “will,” “would,” and similar expressions. Actual results might differ materially from those explicit or implicit in the forward-looking statements. Important factors that could cause actual results to differ materially include: the development stage of our primary clinical candidates and related risks involved in drug development, clinical trials, regulation, manufacturing and commercialization; risks related to counterparty performance, including our reliance on third parties for success in certain areas of Athenex’s business; our history of operating losses and need to raise additional capital; uncertainties around our ability to meet funding conditions under our financing agreements and access to capital thereunder; risks and uncertainties related to the COVID-19 pandemic and its potential impact on our operations, cash flow and financial condition; competition; intellectual property risks; risks relating to doing business internationally and in China; the risk of production slowdowns or stoppages or other interruptions at our Chongqing facilities; and the other risk factors set forth from time to time in our SEC filings, copies of which are available for free in the Investor Relations section of our website at http://ir.athenex.com/phoenix.zhtml?c=254495&p=irol-sec or upon request from our Investor Relations Department. All information provided in this release is as of the date hereof and we assume no obligation and do not intend to update these forward-looking statements, except as required by law.
Contacts
Investors:
Steve Rubis
Athenex, Inc.
Email: stevenrubis@athenex.com
Daniel Lang, MD
Athenex, Inc.
Email: danlang@athenex.com
Tim McCarthy
LifeSci Advisors, LLC
Email: tim@lifesciadvisors.com
FAQ
What is the date of Athenex's first quarter 2021 financial update?
What time is the Athenex conference call for the financial update?
How can I participate in Athenex's conference call?
What ticker symbol does Athenex trade under?
Where can I find more information about Athenex's products?
